Why the study?
Does intravenous p-chlorophenoxyisobutyrate reduce epicardial ST-segment elevation during coronary occlusion in dogs?
Does intravenous p-chlorophenoxyisobutyrate reduce epicardial ST-segment elevation during coronary occlusion in dogs?
In a canine model of coronary occlusion, antilipolytic therapy with CPIB reduced arterial free fatty acid concentrations and myocardial ischemic injury as measured by ST-segment elevation.
No takes yet. Share an insight, caveat, or question.
Antilipolytic therapy attenuated ischemic injury in canine occlusion; hypothesis-generating for human ACS trials, should not change practice.
Μjøs et al. (1976) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: